Table 1

Baseline radiographic data

PlaceboGolimumab 50 mgGolimumab 100 mg
Patients randomised, n78138140
Patients with evaluable radiographs, n66111122
 mSASSS
  Mean±SD16.1±18.711.7±16.413.5±18.9
  Median (IQR)7.9 (1.0, 28.0)3.1 (0.5, 18.0)3.5 (0.5, 18.0)
   p Value vs placebo0.270.49
 Patients with syndesmophytes at baseline and ≥1 follow-up evaluation,* n (%)40 (60.6%)68 (61.3%)71 (58.2%)
  • *Defined as ≥1 level of spine with a score ≥2 (syndesmophytes) for ≥1 reader.

  • mSASSS, modified Stoke Ankylosing Spondylitis Spine Score.